Search Results - Joseph Boni

  • Showing 1 - 4 results of 4
Refine Results
  1. 1

    Assessment of clinical immunogenicity of inotuzumab ozogamicin in patients with non-Hodgkin lymphoma and acute lymphoblastic leukemia by Darshana Jani, John Nowak, Ying Chen, Joseph Boni, Boris Gorovits

    Published in AAPS Open (2018-02-01)
    Get full text
    Article


  2. 2

    In relapsed or refractory diffuse large B‐cell lymphoma, CD19 expression by immunohistochemistry alone is not a predictor of response to loncastuximab tesirine by Paolo F. Caimi, Mehdi Hamadani, Carmelo Carlo‐Stella, Masoud Nickaeen, Eric Jordie, Kiersten Utsey, Tim Knab, Francesca Zammarchi, Danilo Cucchi, Serafino Pantano, Karin Havenith, Ying Wang, Joseph Boni

    Published in eJHaem (2024-02-01)
    Get full text
    Article


  3. 3

    Inotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: a phase 1/2 study by Daniel J. DeAngelo, Wendy Stock, Anthony S. Stein, Andrei Shustov, Michaela Liedtke, Charles A. Schiffer, Erik Vandendries, Katherine Liau, Revathi Ananthakrishnan, Joseph Boni, A. Douglas Laird, Luke Fostvedt, Hagop M. Kantarjian, Anjali S. Advani

    Published in Blood Advances (2017-06-01)
    Get full text
    Article


  4. 4

    608 Results of a phase 1 study investigating camidanlumab tesirine as monotherapy and in combination with pembrolizumab in patients with selected advanced solid tumors by Igor Puzanov, Shivaani Kummar, Sylvie Rottey, Patricia LoRusso, Kyriakos P Papadopoulos, Erika Hamilton, Josef Rüschoff, Fiona C Thistlethwaite, Nuria Kotecki, Christopher T Chen, Yvan LeBruchec, Jerzy Dyczkowski, Sara Samari, Marie Toukam, Joseph Boni, Karin Havenith, Serafino Pantano

    Published in Journal for ImmunoTherapy of Cancer (2023-11-01)
    Article


Search Tools: